Telomelysin

Drug Profile

Telomelysin

Alternative Names: OBP-301; Telomelysin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncolys Biopharma
  • Developer Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Oncolytic viruses; Viral proteins
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Head and neck cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Oesophageal cancer
  • Phase I Solid tumours
  • Preclinical Neuroblastoma
  • No development reported Adenocarcinoma; Breast cancer; Mesothelioma; Osteosarcoma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Adenocarcinoma in USA (Intratumoural, Injection)
  • 01 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (Intratumoural) (NCT03172819)
  • 07 Jul 2017 Oncolys BioPharma enrols the first patient in a phase I trial for Oesophageal cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top